In those trials, AHI fell by 25.3 and 29.3 events an hour on tirzepatide, against 5.3 and 5.5 on placebo.1,2
What the numbers mean
An AHI of 15 or more counts as moderate to severe sleep apnea, the threshold the Zepbound trials used for entry.2 The Zepbound label uses lower numbers to define the best outcome. Remission or mild apnea without symptoms means an AHI under 5, or an AHI of 5 to 14 with a low score on a daytime sleepiness questionnaire, the Epworth Sleepiness Scale.2 So in rough terms, under 5 is normal, 5 to 14 mild, and 15 or more moderate to severe in how these trials sorted people.
Because AHI is a count per hour of sleep, it is measured overnight.1 The people in the Zepbound trials were far above the threshold. The label's baseline table shows that about two thirds had severe apnea, 63.1% in the first trial and 68.2% in the second. Most also had other conditions linked to weight: high blood pressure in about three in four and prediabetes in more than half.2
What tirzepatide did to it
SURMOUNT-OSA was two 52-week trials in adults with obesity and moderate to severe sleep apnea: one in people not using a positive airway pressure machine at night, and one in people who were. At the start, AHI averaged 51.5 and 49.5 events an hour.1
- Without a machine: −25.3 on tirzepatide against −5.3 on placebo, a difference of 20.0.
- With a machine: −29.3 against −5.5, a difference of 23.8.
- Remission or mild apnea without symptoms: 42.2% against 15.9% in the first trial, 50.2% against 14.3% in the second.
- Weight fell by 17.7% and 19.6% on tirzepatide, against 1.6% and 2.3% on placebo.
Malhotra et al., 2024; ZEPBOUND label, Table 9.1,2
On that basis, Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity, at 10 mg or 15 mg a week.2 Our page on the Zepbound dosing schedule shows the climb to those doses.
Beyond the count
AHI counts events but not how deep they go. The Zepbound label also reports the sleep apnea-specific hypoxic burden, measured in percent-minutes per hour, which reflects how far and for how long oxygen levels dropped. In the first trial it fell by 95.2 on tirzepatide against 25.1 on placebo, from starting values of 153.6 and 137.8.2
Other drugs measured by AHI
Retatrutide, an experimental triple agonist, was also tested on AHI in a subgroup of 243 people with sleep apnea in its TRIUMPH-1 trial. AHI fell by 34.3 and 31.7 events an hour on 9 mg and 12 mg, against 9.9 on placebo.3 It has no U.S. label from its maker as of November 20, 2026.
Reading a change in AHI
A fall from about 50 to about 22 or 25 events an hour is large, but it still leaves many people above 15, in the moderate range. That is why the trial in people who kept their machine matters: they gained from the drug on top of it. Whether someone can stop using a machine after losing weight is a decision for a sleep doctor, based on a repeat sleep study, not on the trial averages.
Sources
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med 2024;391:1193-1205. Funded by Eli Lilly. doi:10.1056/NEJMoa2404881
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2 and 14.2. accessdata.fda.gov
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med 2026;395:1781-1793. doi:10.1056/NEJMoa2604169
Related analyses
Zepbound dosing schedule: every step from 2.5 to 15 mg, with your dates
Mounjaro vs Zepbound: the same drug under two labels, compared by use, results and price
Zepbound cost: what you pay with insurance, without it, and over a year
Zepbound side effects timeline: when they start, how long they last, when they ease
Log your weight and how you sleep, and see whether they move together.
Open Dose Insider